Stocktoria
CARLSMED, INC. CARL
CARLSMED, INC. (CARL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $50.5M at a -58.7% net margin.
Beneish M-score: -1.8 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.864 |
| Retained earnings / assets | -0.775 |
| EBIT / assets | -0.235 |
| Equity / liabilities | 3.164 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| APYX | Apyx Medical Corp | 5/9 | -0.11 | — | +9.9% |
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
| CVRX | CVRx, Inc. | 3/9 | -15.5 | — | +10.4% |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
| LNSR | LENSAR, Inc. | 2/9 | -10.17 | — | +9.2% |
About CARLSMED, INC.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
FAQ
Is CARL financially healthy?
CARLSMED, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CARL pay a dividend?
No, CARLSMED, INC. does not currently pay a dividend.
How profitable is CARL?
In FY2025, CARLSMED, INC. had a net margin of -58.7% and a return on equity of -30.0%.
What is the analyst price target for CARL?
The average Wall-Street price target for CARLSMED, INC. is $18.40, about 34.1% above the recent price, from 5 analysts.
Is CARL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CARLSMED, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.